Trastuzumab (trade name Herceptin) is a humanized monoclonal antibody to the extracellular domain of the HER2/neu (ErbB2), a transmembrane receptor overexpressed on the surface of approximately 15–30% of breast cancer cells. This evidence concerns the gene ERBB2 and breast carcinoma.